pCPA receives FDA Orphan Drug Designation for monoamine oxidase deficiency

The FDA has granted Orphan Drug Designation to para-chloro-phenylalanine (pCPA) for monoamine oxidase deficiency (MAOD), a rare X-linked neurodevelopmental disorder associated with impaired monoamine oxidase A and/or B enzyme activity, according to an announcement from the Monoamine Oxidase Deficiency Foundation.¹

The designation does not establish efficacy or safety and is not equivalent to FDA approval. However, it may support future development through incentives such as tax credits for qualified clinical testing, exemption from certain FDA fees, and potential market exclusivity if the product is ultimately approved for the designated indication.² The Foundation said it was formed because “families could not afford to wait for progress,” and described the designation as a step toward therapeutic development for patients with MAOA deficiency and combined MAO-A/B deficiency.¹

MAOD is characterized by the disruption of monoamine metabolism involving neurotransmitters such as serotonin, dopamine, and norepinephrine. The Foundation’s announcement described affected patients as having markedly elevated serotonin levels and clinical features that may include developmental delay, intellectual disability, autism, and growth impairment.¹ For pediatricians, the regulatory action is most relevant as an early signal of drug-development activity in an ultrarare disorder for which diagnosis may be delayed, and disease-specific treatment guidance remains limited.

pCPA is a serotonin synthesis inhibitor that has been studied historically as a pharmacologic tool for lowering serotonin. The compound, also known as parachlorophenylalanine, inhibits tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis. In early pharmacology studies, pCPA depleted brain serotonin, a property that has limited its therapeutic use in other contexts because central serotonin lowering may be associated with neuropsychiatric and neurologic adverse effects.³

The Foundation’s rationale for MAOD differs from prior uses of the compound. According to the announcement, pCPA previously lowered body serotonin in patients but also lowered normal serotonin levels in the brain, causing adverse effects. In MAOD, the Foundation stated, serotonin may be extremely elevated in both the periphery and central nervous system; therefore, the compound’s ability to cross into the brain may be considered a potential advantage rather than only a liability.¹ This remains a therapeutic hypothesis, and no clinical trial results in MAOD were reported in the announcement.

The genetic and clinical basis for MAO-related disorders has been recognized for decades. In 1993, Brunner and colleagues reported a point mutation affecting monoamine oxidase A in a Dutch kindred with abnormal behavioral phenotype, providing early evidence that MAOA disruption can have clinically significant neurodevelopmental and behavioral consequences.⁴ Since then, recognition of MAOA deficiency and combined MAOA/MAOB deficiency has expanded, but the patient population remains very small, and published treatment evidence is sparse.

Orphan drug designation is available for drugs and biologics intended to treat diseases or conditions affecting fewer than 200,000 people in the United States, or for which there is no reasonable expectation that development and marketing costs would be recovered from US sales.² The designation is intended to encourage development in rare diseases, but it does not mean that the FDA has determined that the drug is effective for the condition. For pCPA, future clinical development would still need to establish an appropriate dosing strategy, pharmacodynamic targets, clinical endpoints, and short- and long-term safety monitoring in a pediatric and neurodevelopmentally vulnerable population.

Current clinical management for MAOD is not standardized and generally depends on genetic diagnosis, symptom-directed care, developmental services, and specialist management of neurologic, behavioral, nutritional, and growth-related complications. The potential role of serotonin-lowering therapy will require careful study because monoamine pathways are central to neurodevelopment, autonomic regulation, sleep, mood, and behavior. Clinicians should be cautious about interpreting the designation as evidence supporting off-label use.

Several questions remain unanswered. The announcement did not describe an active clinical trial, planned enrollment criteria, outcome measures, proposed age range, biomarkers, or safety-monitoring framework. It also did not report patient-level data, efficacy outcomes, or adverse event rates in MAOD. Next steps will likely require natural history characterization, validated clinical and biochemical endpoints, and prospective evaluation of whether serotonin reduction translates into meaningful developmental, neurologic, behavioral, or growth-related benefit.

References

1. Monoamine Oxidase Deficiency Foundation. FDA grants Monoamine Oxidase Deficiency Orphan Drug Designation. PRNewswire. June 12, 2026. Accessed June 16, 2026. https://www.prnewswire.com/news-releases/fda-grants-monoamine-oxidase-deficiency-orphan-drug-designation-302798613.html

2. US Food and Drug Administration. Orphan Drug Act, 21 USC §360bb.

3. Koe BK, Weissman A. p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther. 1966;154(3):499-516.

4. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science. 1993;262(5133):578-580.